Bruce Robertson Managing Director & Co-Head of BioHealth



EducationB.S.E. and B.A., University of Pennsylvania
Ph.D., University of Delaware
M.B.A., Harvard Business School

Prior ExperienceToucan Capital
GIV Venture Partners
IGEN International
W.R. Grace & Co.

As Managing Director of H.I.G. BioHealth Partners, Bruce focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics.

Bruce currently serves on the boards of Apollo Endosurgery, RxSight, CardioFocus, Iconic Therapeutics, Exagen, and Augmedics.

Bruce has been active in the life sciences sector for more than 30 years. Prior to joining H.I.G., Bruce served most recently as Managing Director at Toucan Capital, a venture capital fund focusing on healthcare investments. While at Toucan, Bruce invested in leading drug and device companies throughout the U.S. Prior to Toucan, Bruce was a General Partner at GIV Venture Partners, a venture capital firm focused on investments in the US, India, and China. Prior to his private equity career, Bruce was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN’s partnering and M&A strategies. Bruce started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices.

Bruce is on the boards of the University of Delaware Research Foundation and the BioLife Fund of Virginia’s Center for Innovative Technology. Bruce holds a B.S.E. in Chemical Engineering and B.A. in Mathematics from the University of Pennsylvania, a Ph.D. in Chemical/Biomedical Engineering from the University of Delaware, and an M.B.A. with High Distinction from Harvard Business School.